Vol. 3 No. 10 (2023): Volume 03 Issue 10
Articles
BIOLOGICAL PROPERTIES OF MEDICINAL HERBS: A COMPREHENSIVE OVERVIEW
Medicinal herbs have been used for centuries as a primary source of healing and healthcare. This article provides a comprehensive overview of the biological properties of medicinal herbs, highlighting their therapeutic potential, mechanisms of action, and the importance of scientific research in unlocking their full medicinal potential. We explore the various categories of biological properties exhibited by these plants, including anti-inflammatory, antioxidant, antimicrobial, and anticancer activities. The article also discusses the challenges and opportunities in harnessing the power of medicinal herbs for modern medicine.
EXPLORING BIOLOGICAL SAMPLES: SERUM METAL ANALYSIS IN CATARACT PATIENTS
This study investigates the potential of utilizing biological samples, specifically serum, for the analysis of metal concentrations in cataract patients. Cataract formation has been associated with metal accumulation in ocular tissues. By employing advanced analytical techniques, we examined the metal profiles in serum samples collected from cataract patients. The study explores the presence of various metals and their potential correlations with cataract severity and progression. The findings shed light on the role of metals in cataract development and offer insights into the potential implications for ocular health.
Revolutionizing Advanced Ovarian Cancer Therapy: A Focus on the PD-1/PD-L1 Pathway
This comprehensive review delves into the cutting-edge advancements in the treatment landscape of advanced ovarian cancer, with a specific focus on the programmed cell death protein 1 (PD-1) and its ligand PD-L1 pathway. Ovarian cancer, often diagnosed at advanced stages, poses significant challenges due to limited effective treatment options. The emergence of immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway has sparked new hope for improved outcomes. This review explores the mechanistic basis of PD-1/PD-L1 interactions, outlines the evolving clinical trials assessing immune checkpoint inhibitors, and discusses the clinical significance of these therapies in reshaping the therapeutic paradigm for advanced ovarian cancer.